LNTH Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

110.999

Open

109.920

VWAP

109.63

Vol

511.12K

Mkt Cap

7.15B

Low

108.000

Amount

56.03M

EV/EBITDA(TTM)

19.57

Total Shares

65.11M

7.23B

EV/OCF(TTM)

17.73

P/S(TTM)

4.80

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.

Events Timeline

(ET)

2026-06-26

16:30:00

Lantheus LNTH-2501 New Drug Application Receives FDA Complete Response Letter

2026-05-22 (ET)

2026-05-22

16:00:00

Lantheus Weighs Sale After Curium Takeover Offer

2026-05-22

16:00:00

Lantheus Weighs Sale to Curium at $7B

2026-05-07 (ET)

2026-05-07

07:20:00

Company Confirms FY26 Revenue View of $1.4B-$1.45B

2026-05-07

07:10:00

Lantheus Reports Q1 Revenue of $377.33M, Beating Consensus

News

9.0

06-29Newsfilter

Lantheus Receives FDA Complete Response Letter for LNTH-2501

9.0

06-26seekingalpha

Lantheus Receives Complete Response Letter from FDA for LNTH-2501

9.0

06-26Newsfilter

Lantheus Faces FDA Setback for LNTH-2501 NDA Approval

2.0

06-23NASDAQ.COM

Lantheus Holdings Stock Surpasses Analyst Target Price

1.0

05-27Newsfilter

Lantheus to Speak at Growth Stock Conference

8.5

05-22Newsfilter

Lantheus Weighs Sale Following $7 Billion Curium Offer

7 Analyst Rating

Wall Street analysts forecast LNTH stock price to rise

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

70.00

Averages

82.17

High

105.00

Current: 0.000

Low

70.00

Averages

82.17

High

105.00

Mizuho

Outperform

maintain

$100 -> $115

AI Analysis

2026-05-27

Reason

Mizuho

Price Target

$100 -> $115

AI Analysis

2026-05-27

maintain

Outperform

Reason

Mizuho raised the firm's price target on Lantheus to $115 from $100 and keeps an Outperform rating on the shares after Bloomberg reported the company is considering a sale to Curium after receiving a takeout offer at an estimated $7B. Mizuho cites bullish Alzheimer's prescription trends for the target boost.

Truist

Buy

maintain

$98 -> $115

2026-05-11

Reason

Truist

Price Target

$98 -> $115

2026-05-11

maintain

Buy

Reason

Truist raised the firm's price target on Lantheus to $115 from $98 and keeps a Buy rating on the shares. Pylarify delivered its 3rd consecutive beat at $241M and flat-to-up sequential revenue growth, suggesting further PYL stabilization, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LNTH

Unlock Now

Valuation Metrics

The current forward P/E ratio for Lantheus Holdings Inc (LNTH.O) is 19.19, compared to its 5-year average forward P/E of 15.92. For a more detailed relative valuation and DCF analysis to assess Lantheus Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

15.92

Current PE

19.19

Overvalued PE

24.05

Undervalued PE

7.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.93

Current EV/EBITDA

16.59

Overvalued EV/EBITDA

13.53

Undervalued EV/EBITDA

6.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.79

Current PS

4.31

Overvalued PS

4.70

Undervalued PS

2.87

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

any good trades for today

Intellectia · 40 candidates

Price: $5.00 - $100.00Volume: >= 1,000,000Price Change Pct: $3.00 - $15.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

DYN

Dyne Therapeutics Inc

2.45B

AXTI

AXT Inc

1.79B

SLDB

Solid Biosciences Inc

525.89M

CAPR

Capricor Therapeutics Inc

1.52B

ICL

ICL Group Ltd

6.38B

TALK

Talkspace Inc

788.52M

2 great growth stocks

Intellectia · 63 candidates

Market Cap: >= 5.00BRegion: USAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 15Eps 5yr Cagr: >= 15Pe Ttm: 10 - 60List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

HOOD

Robinhood Markets Inc

69.80B

SCHW

Charles Schwab Corp

169.43B

BKNG

Booking Holdings Inc

131.86B

ATAT

Atour Lifestyle Holdings Ltd

5.66B

FUTU

Futu Holdings Ltd

21.12B

Permian Resources Corp

14.60B

list 4 promising quantum computing stocks

Intellectia · 294 candidates

Market Cap: >= 500.00MBeta: LowRisk, ModerateRiskRevenue 5yr Cagr: >= 10Eps 5yr Cagr: >= 0

Ticker

Name

Market Cap$

LBRDA

Liberty Broadband Corp

6.25B

FRHC

Freedom Holding Corp

7.61B

CIVI

Civitas Resources Inc

2.32B

DLO

Dlocal Ltd

3.98B

OWL

Blue Owl Capital Inc

24.58B

CCB

Coastal Financial Corp (EVERETT)

1.73B

Whales Holding LNTH

Portolan Capital Management, LLC

Reinhart Partners, LLC

Deerfield Management Company, L.P.

Farallon Capital Management, L.L.C.

Vestal Point Capital, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Lantheus Holdings Inc (LNTH) stock price today?

The current price of LNTH is 109.89 USD — it has increased 0.85

What is Lantheus Holdings Inc (LNTH)'s business?

What is the price predicton of LNTH Stock?

Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is82.17 USD with a low forecast of 70.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.